The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | Long-term quality of life after GI cancer surgery: nutritional impact & surveillance
Jessie Elliott, FRCS, PhD, Trinity St. James’s Cancer Institute, Dublin, Ireland, discusses two focus areas in long-term quality of life after esophageal and gastric cancer surgery: nutritional impact and surveillance. The effect of surgery on gastrointestinal physiology and eating habits is explored, with a focus on the exaggerated gut hormone response, specifically glucagon-like peptide 1. The second area of focus is the surveillance of patients after treatment to identify potential cancer recurrence. Dr Elliott highlights the SANG2 trial, an international multicentre clinical trial, that explores different intensities of surveillance after treatment completion. The trial aims to assess the impact of intensive follow-up on oncological outcomes while considering the potential negative impact on quality of life.
This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
